Willow Biosciences Inc (ATLE) AI Stock Analysis

Top Page

Willow Biosciences Inc

(TSXV:ATLE)

Select Model

Rating:50Neutral

Price Target:CAD 0.15▲(66.67% Upside)

Action:reiterated

Date:12/07/25

The overall stock score is primarily impacted by significant financial challenges, including negative equity and ongoing losses, which are major concerns. However, positive technical indicators and favorable corporate events provide some optimism for future performance.

Positive Factors

Rapid Revenue GrowthA nearly 300% revenue increase signifies accelerating product adoption and expanding customer traction for Willow's fermentation-derived ingredients. This durable top-line momentum supports scale effects, improves leverage on fixed costs, and strengthens the case for continued commercial expansion over the next several months.

Negative Factors

Negative Shareholders' EquityNegative equity indicates solvency strain and weak balance sheet resilience. This structural weakness limits borrowing capacity, raises creditor and investor concerns, and increases the likelihood of dilutive financing or onerous terms—factors that materially affect strategic flexibility for months ahead.

Willow Biosciences Inc (ATLE) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 41.96M
Dividend Yield: ―
Average Volume (3M): 82.88K
Price to Earnings (P/E): -0.8
Beta (1Y): 1.34
Revenue Growth: -100.00%
EPS Growth: 94.43%
Country: Canada
Employees: 19
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Willow Biosciences Inc Business Overview & Revenue Model

Company Description

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and...

How the Company Makes Money

null

Willow Biosciences Inc Financial Statement Overview

Summary

Willow Biosciences Inc shows strong revenue growth, yet continues to grapple with significant financial challenges, including sustained losses, negative equity, and cash flow constraints. While there are glimmers of operational improvement, substantial efforts are required to achieve financial stability.

Income Statement

32Negative

Balance Sheet

25Negative

Cash Flow

30Negative

Willow Biosciences Inc Technical Analysis

Technical Analysis SentimentNegative

Last Price0.09

Price Trends

50DMA0.12Negative

100DMA0.13Negative

200DMA0.15Negative

Market Momentum

MACD-0.01Positive

RSI30.75Neutral

STOCH19.76Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ATLE, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.12, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 30.75 is Neutral, neither overbought nor oversold. The STOCH value of 19.76 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ATLE.

Willow Biosciences Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TSE:ATLE against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TSE:DB	52Neutral	CAD 69.31M	-112.50	-1.06%	―	26.44%	-104.43%
TSE:ATLE	50Neutral	CAD 41.96M	-0.76	-2099.75%	―	-100.00%	94.43%
TSE:VEXT	49Neutral	CAD 60.69M	-2.49	-25.01%	―	13.60%	11.06%
TSE:BNXT	41Neutral	CAD 35.38M	-3.52	117.02%	―	―	―
TSE:IAN	41Neutral	CAD 34.87M	-0.49	50.32%	―	-11.58%	-1950.00%

* General Sector Average

Performance Comparison

TSE:ATLE and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:ATLE	Willow Biosciences	0.09	-0.07	-43.75%
TSE:IAN	Ianthus Capital Holdings (OTC)	0.01	0.00	0.00%
TSE:DB	Decibel Cannabis Company Inc	1.80	-0.30	-14.29%
TSE:VEXT	Vext Science	0.24	-0.03	-9.26%
TSE:BNXT	Bionxt Solutions Inc	0.26	-0.57	-68.67%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 07, 2025

Willow Biosciences Inc AI Stock Analysis

Top Page